FMED Fidelity Disruptive Medicine ETF

ETF on NASDAQ (US) · Actively managed · Listing

Form N-PORT Aug 31, 2026 vs May 31, 2026 Filed with the SEC Oct 26, 2026
Book +19% $45.2M → $53.8M
Line items (May 31, 2026: 70) 74
In top 10 34%
Largest holding: 10x Genomics, Inc. ($2.67M) 5.0%
Portfolio date Aug 31, 2026
New / increased 14 / 24
Reduced / closed 14 / 10
Unchanged 20
−45%

Most notable sale · LifeStance Health Group, Inc.

LifeStance Health Group, Inc. cut by 45%

Shares went from 227,100 to 124,900 ($1.75M → $1.54M). Now 2.9% of the portfolio. Estimated trade $1.26M.

New

Most notable buy · Illumina, Inc.

New position in Illumina, Inc.

6,800 shares worth $1.45M. Now 2.7% of the portfolio.

Largest holding: 10x Genomics, Inc., cut 5%, 42,800 shares ($2.67M).

10x Genomics, Inc.: 5.0% Fidelity Revere Street Trust: 4.2% Thermo Fisher Scientific Inc: 3.7% Danaher Corporation: 3.6% Natera, Inc.: 3.2% argenx SE: 3.1% LifeStance Health Group, Inc.: 2.9% Revolution Medicines, Inc.: 2.7% Illumina, Inc.: 2.7% Moderna, Inc.: 2.6% The other 64 positions: 66.4% $53.8M Holdings value
Current positions Top 10 % of book
10x Genomics, Inc. TXG $2.67M · −5% sh 5.0%
Fidelity Revere Street Trust $2.28M · −46% units 4.2%
Thermo Fisher Scientific Inc TMO $1.97M · 2.5x sh 3.7%
Danaher Corporation DHR $1.92M · +17% sh 3.6%
Natera, Inc. NTRA $1.70M · 2x sh 3.2%
argenx SE ARGX $1.65M · +17% sh 3.1%
LifeStance Health Group, Inc. LFST $1.54M · −45% sh 2.9%
Revolution Medicines, Inc. RVMD $1.48M · +60% sh 2.7%
Illumina, Inc. ILMN $1.45M · NEW 2.7%
Moderna, Inc. MRNA $1.40M · −45% sh 2.6%

Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.

Healthcare: 87.7% Technology: 3.0% Unclassified: 9.3% 2 sectors
Sectors % of holdings value
Healthcare 87.7%
Technology 3.0%
Unclassified 9.3%
Biotechnology: 46.6% Diagnostics & Research: 12.0% Medical Devices: 10.2% Medical Instruments & Supplies: 7.8% Medical Care Facilities: 4.3% Health Information Services: 2.5% Software - Application: 2.5% Other (4): 5.0% Unclassified: 9.3% 11 industries
Industries % of holdings value
Biotechnology 46.6%
Diagnostics & Research 12.0%
Medical Devices 10.2%
Medical Instruments & Supplies 7.8%
Medical Care Facilities 4.3%
Health Information Services 2.5%
Software - Application 2.5%
Other (4) 5.0%
Unclassified 9.3%
Initiations 14 Value
Illumina, Inc. ILMN 2.7% of portfolio $1.45M
West Pharmaceutical Services, Inc. WST 1.6% of portfolio $887K
Twist Bioscience Corporation TWST 1.3% of portfolio $695K
Dianthus Therapeutics, Inc. DNTH 0.8% of portfolio $422K
Alumis Inc. ALMS 0.8% of portfolio $410K
Praxis Precision Medicines, Inc. PRAX 0.7% of portfolio $350K
Bruker Corporation BRKR 0.6% of portfolio $313K
Braveheart Bio, Inc. BRVE 0.5% of portfolio $255K
PHARVARIS BV 0.5% of portfolio $246K
CG Oncology, Inc. CGON 0.4% of portfolio $210K
Climb Bio, Inc. CLYM 0.4% of portfolio $198K
Definium Therapeutics, Inc. DFTX 0.4% of portfolio $191K
Increases 24 Change
Thermo Fisher Scientific Inc TMO $628K → $1.97M 2.5x
Natera, Inc. NTRA $584K → $1.70M 2x
Revolution Medicines, Inc. RVMD $709K → $1.48M +60%
Sartorius Stedim Biotech S.A. DIM $755K → $1.32M +60%
Oruka Therapeutics, Inc. ORKA $58.5K → $556K 6x
Repligen Corporation RGEN $308K → $760K +69%
Alnylam Pharmaceuticals, Inc. ALNY $1.14M → $1.20M +32%
Danaher Corporation DHR $1.40M → $1.92M +17%
argenx SE ARGX $1.14M → $1.65M +17%
Spyre Therapeutics, Inc. SYRE $22.1K → $232K 8.7x
Relay Therapeutics, Inc. RLAY $183K → $441K +85%
Roivant Sciences Ltd. ROIV $337K → $563K +44%
Reductions 14 Change
LifeStance Health Group, Inc. LFST $1.75M → $1.54M −45%
Moderna, Inc. MRNA $863K → $1.40M −45%
UCB SA UCB $1.94M → $825K −50%
Veeva Systems Inc. VEEV $730K → $857K −28%
Xenon Pharmaceuticals Inc. XENE $786K → $558K −36%
Caris Life Sciences, Inc. CAI $702K → $765K −29%
DexCom, Inc. DXCM $482K → $364K −39%
Kymera Therapeutics, Inc. KYMR $814K → $1.01M −15%
Alignment Healthcare, Inc. ALHC $511K → $297K −33%
10x Genomics, Inc. TXG $1.27M → $2.67M −5%
UnitedHealth Group Incorporated UNH $922K → $818K −13%
Veracyte, Inc. VCYT $631K → $519K −12%
Terminations 10 Change
Bio-Techne Corp TECH was $919K −100%
Crinetics Pharmaceuticals, Inc. CRNX was $675K −100%
Cytokinetics, Incorporated CYTK was $634K −100%
Privia Health Group, Inc. PRVA was $605K −100%
Stryker Corporation SYK was $559K −100%
Lonza Group Ltd O6Z was $500K −100%
NUVALENT INC was $497K −100%
Insulet Corporation PODD was $451K −100%
Align Technology, Inc. ALGN was $326K −100%
PROCEPT BioRobotics Corporation PRCT was $175K −100%

The other 2 initiations

Jade Biosciences, Inc. ($159K), Annexon, Inc. ($119K)

The other 2 reductions

Waystar Holding Corp. (−11%), Intuitive Surgical, Inc. (−1%)

Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

Fidelity® Disruptive Medicine ETF seeks long-term growth of capital.

Principal investment strategies

Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services. Disruptive medicine companies are companies that have or are developing innovative ways of doing business that may be disruptive in the development, design, manufacture, or distribution of products, processes, or services in the medical field. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, precision medicine, advanced diagnostics and consumer wellness. In pursuing this investment theme, the fund may invest in companies in any economic sector. Although the fund may invest across economic sectors, the fund concentrates its investments in the health care industries. Fidelity may consider a company to fit within the disruptive theme if it meets one or more of the following criteria: (i) the company has new and/or evolving business models that have the potential to transform an industry or challenge incumbents, (ii) the company is early to market with a product or solution that has the potential to substantially impact the industry, (iii) the company possesses competitive advantages that set it apart from its competitors, (iv) the company issues patents for innovative products or services with high potential impact in the market, or (v) the company's long-term financial outlook is positioned to benefit substantially from innovation and research and development conducted by the company. Derivative instruments that provide investment exposure to the investments above or exposure to one or more market risk factors associated with such investments are included in the fund's 80% policy, consistent with the fund's investment policies and limitations with respect to investments in derivatives. Normally investing primarily in equity securities. Using fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments with quantitative portfolio construction. Investing in either "growth" stocks or "value" stocks or both. Investing in securities of domestic and foreign issuers.

Management and Contact

Adviser
Fidelity Management & Research Company LLC
Portfolio managers

Michael Kim (Co-Portfolio Manager) has managed the fund since 2023.

Eddie Yoon (Co-Portfolio Manager) has managed the fund since 2025.

Track Record as of Dec 31, 2025

1 Year 5 Years Since Inception
Return Before Taxes 9.69% -0.21% 3.37%
Return After Taxes on Distributions 9.69% -0.31% 3.31%
Return After Taxes on Distributions and Sale of Fund Shares 5.74% -0.19% 2.56%
MSCI ACWI (All Country World Index) Index (reflects no deduction for fees or expenses) 22.71% 11.56% 19.90%
MSCI All Country World Health Care Equal Weighted Index (reflects no deduction for fees or expenses) 11.74% -2.23% 3.77%

Holdings as of Aug 31, 2026

74 lines, 68 linked, weights sum to 104.45% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
10X GENOMICS INC US88025U1097 Equity 42,800 −2,200 5.19% $ 2.673M
Fidelity Revere Street Trust
US31635A3032 Money market 2,284,300.649 −1,921,797.821 4.43% $ 2.285M
THERMO FISHER SCIENTIFIC INC US8835561023 Equity 3,200 +1,924 3.83% $ 1.975M
DANAHER CORP US2358511028 Equity 9,000 +1,325 3.73% $ 1.922M
NATERA INC US6323071042 Equity 5,280 +2,665 3.30% $ 1.7M
ARGENX SE US04016X1019 Equity 1,600 +235 3.20% $ 1.651M
LIFESTANCE HEALTH GROUP INC US53228F1012 Equity 124,900 −102,200 3.00% $ 1.544M
REVOLUTION MEDICINES INC US76155X1000 Equity 7,200 +2,696 2.87% $ 1.48M
ILLUMINA INC US4523271090 Equity 6,800 new +6,800 2.82% $ 1.453M
MODERNA INC US60770K1079 Equity 10,000 −8,282 2.72% $ 1.403M
HEARTFLOW INC US42238D1072 Equity 26,500 +1,506 2.59% $ 1.335M
SARTORIUS STEDIM BIOTECH FR0013154002 Equity 5,800 +2,167 2.56% $ 1.32M
ALNYLAM PHARMACEUTICALS INC US02043Q1076 Equity 5,000 +1,209 2.33% $ 1.203M
COGENT BIOSCIENCES INC US19240Q2012 Equity 34,000 +572 2.31% $ 1.19M
INTUITIVE SURGICAL INC US46120E6023 Equity 2,800 −16 2.05% $ 1.055M
ASCENDIS PHARMA A/S
DK0060615755 Equity 3,865 0 1.97% $ 1.017M
KYMERA THERAPEUTICS INC US5015751044 Equity 8,500 −1,500 1.96% $ 1.01M
INSMED INC US4576693075 Equity 7,775 +900 1.84% $ 947.151K
VAXCYTE INC US92243G1085 Equity 15,571 +1,500 1.83% $ 945.783K
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
GB00BRXB0C07 Equity 12,000 0 1.83% $ 943.56K
EDWARDS LIFESCIENCES CORP US28176E1082 Equity 10,000 0 1.76% $ 907.5K
WEST PHARMACEUTICAL SVCS INC US9553061055 Equity 2,600 new +2,600 1.72% $ 886.886K
VEEVA SYS INC US9224751084 Equity 3,000 −1,188 1.66% $ 857.07K
UCB SA BE0003739530 Equity 3,300 −3,305 1.60% $ 825.27K
UNITEDHEALTH GROUP INC US91324P1021 Equity 2,100 −324 1.59% $ 817.761K
AMYLYX PHARMACEUTICALS INC US03237H1014 Equity 23,554 0 1.54% $ 794.948K
GUARDANT HEALTH INC US40131M1099 Equity 4,975 +600 1.53% $ 791.125K
CARIS LIFE SCIENCES INC US1421521071 Equity 30,000 −11,991 1.48% $ 764.7K
REPLIGEN CORP US7599161095 Equity 4,200 +1,715 1.47% $ 760.116K
LEGEND BIOTECH CORP US52490G1022 Equity 36,000 +1,386 1.45% $ 748.08K
BRIGHTSPRING HEALTH SERVICES INC US10950A1060 Equity 12,800 +2,613 1.45% $ 747.52K
VIRIDIAN THERAPEUTICS INC US92790C1045 Equity 31,100 0 1.40% $ 720.276K
TWIST BIOSCIENCE CORP US90184D1000 Equity 5,000 new +5,000 1.35% $ 695K
ENLIVEN THERAPEUTICS INC US29337E1029 Equity 12,000 +1,297 1.35% $ 694.68K
BOSTON SCIENTIFIC CORP US1011371077 Equity 12,185 0 1.14% $ 588.536K
KESTRA MEDICAL TECHNOLOGIES INC BMG524411052 Equity 22,000 +3,600 1.10% $ 566.5K
ROIVANT SCIENCES LTD BMG762791017 Equity 16,250 +5,000 1.09% $ 562.9K
XENON PHARMACEUTICALS INC CA98420N1050 Equity 9,266 −5,100 1.08% $ 557.999K
ORUKA THERAPEUTICS INC US6876041087 Equity 6,000 +5,000 1.08% $ 555.72K
AXSOME THERAPEUTICS INC US05464T1043 Equity 2,752 0 1.06% $ 546.327K
DISC MEDICINE INC US2546041011 Equity 6,926 0 1.06% $ 544.73K
VERACYTE INC US92337F1075 Equity 12,021 −1,600 1.01% $ 519.187K
STOKE THERAPEUTICS INC US86150R1077 Equity 15,670 0 0.95% $ 488.904K
WAYSTAR HOLDING CORP US9467841055 Equity 18,000 −2,187 0.91% $ 471.24K
ELI LILLY and CO US5324571083 Equity 395 0 0.89% $ 456.908K
RELAY THERAPEUTICS INC US75943R1023 Equity 24,000 +11,004 0.86% $ 441.12K
MBX BIOSCIENCES INC US55287L1017 Equity 7,000 +1,872 0.84% $ 431.2K
DIANTHUS THERAPEUTICS INC US2528281080 Equity 4,000 new +4,000 0.82% $ 422.44K
IRHYTHM TECHNOLOGIES INC US4500561067 Equity 3,471 0 0.80% $ 412.841K
ALUMIS INC US0223071020 Equity 18,800 new +18,800 0.80% $ 410.028K
ZAI LAB LTD US98887Q1040 Equity 15,273 0 0.75% $ 388.851K
NEWAMSTERDAM PHARMA COMPANY NV
NL00150012L7 Equity 15,000 +3,878 0.74% $ 380.1K
CYTOMX THERAPEUTICS INC US23284F1057 Equity 112,069 0 0.73% $ 376.552K
DEXCOM INC US2521311074 Equity 4,000 −2,533 0.71% $ 364.24K
PRAXIS PRECISION MEDICINES INC. US74006W2070 Equity 1,000 new +1,000 0.68% $ 350.3K
ZENAS BIOPHARMA INC US98937L1052 Equity 9,817 0 0.62% $ 317.285K
BRUKER CORP US1167941087 Equity 5,400 new +5,400 0.61% $ 313.254K
ALIGNMENT HEALTHCARE INC US01625V1044 Equity 22,200 −11,178 0.58% $ 297.48K
BRAVEHEART BIO INC US10567X1019 Equity 10,000 new +10,000 0.49% $ 255K
PHARVARIS BV
NL00150005Y4 Equity 7,100 new +7,100 0.48% $ 245.731K
SPYRE THERAPEUTICS INC US00773J2024 Equity 2,600 +2,300 0.45% $ 232.258K
MIRUM PHARMACEUTICALS INC US6047491013 Equity 2,191 0 0.42% $ 214.828K
JANUX THERAPEUTICS INC US47103J1051 Equity 11,754 0 0.42% $ 214.158K
STRUCTURE THERAPEUTICS INC US86366E1064 Equity 4,628 0 0.41% $ 212.471K
CG ONCOLOGY INC US1569441009 Equity 2,800 new +2,800 0.41% $ 210.448K
CLIMB BIO INC US28658R1068 Equity 14,400 new +14,400 0.38% $ 197.712K
DEFINIUM THERAPEUTICS INC CA24477V1058 Equity 4,800 new +4,800 0.37% $ 190.656K
VIKING THERAPEUTICS INC US92686J1060 Equity 5,422 0 0.34% $ 177.733K
UPSTREAM BIO INC US91678A1079 Equity 24,900 0 0.32% $ 164.838K
JADE BIOSCIENCES INC US0080642061 Equity 7,426 new +7,426 0.31% $ 158.619K
OLEMA PHARMACEUTICALS INC US68062P1066 Equity 14,950 +3,700 0.30% $ 155.929K
Fidelity Revere Street Trust
US31635A1051 Money market 130,560.229 +11,910.546 0.25% $ 130.586K
OUTSET MEDICAL INC US6901452069 Equity 34,000 0 0.25% $ 129.88K
ANNEXON INC US03589W1027 Equity 24,000 new +24,000 0.23% $ 118.56K

Trades May 31, 2026 to Aug 31, 2026

Holding Ticker Action Before After Change Value
ILLUMINA INC New — 6,800 +6,800 $ 1.453M
LIFESTANCE HEALTH GROUP INC Sold 227,100 124,900 −102,200 $ -1.263M
THERMO FISHER SCIENTIFIC INC Bought 1,276 3,200 +1,924 $ 1.187M
MODERNA INC Sold 18,282 10,000 −8,282 $ -1.162M
BIO TECHNE CORP Closed 17,786 — −17,786 $ -919.18K
WEST PHARMACEUTICAL SVCS INC New — 2,600 +2,600 $ 886.886K
NATERA INC Bought 2,615 5,280 +2,665 $ 858.023K
UCB SA Sold 6,605 3,300 −3,305 $ -826.52K
TWIST BIOSCIENCE CORP New — 5,000 +5,000 $ 695K
CRINETICS PHARMACEUTICALS INC Closed 19,000 — −19,000 $ -675.45K
CYTOKINETICS INC Closed 8,262 — −8,262 $ -634.191K
PRIVIA HEALTH GROUP INC Closed 28,119 — −28,119 $ -604.84K
STRYKER CORP Closed 1,832 — −1,832 $ -558.925K
REVOLUTION MEDICINES INC Bought 4,504 7,200 +2,696 $ 554.217K
LONZA GROUP AG Closed 780 — −780 $ -500.047K
NUVALENT INC
Closed 4,504 — −4,504 $ -497.197K
SARTORIUS STEDIM BIOTECH Bought 3,633 5,800 +2,167 $ 493.347K
ORUKA THERAPEUTICS INC Bought 1,000 6,000 +5,000 $ 463.1K
INSULET CORP Closed 3,112 — −3,112 $ -451.053K
DIANTHUS THERAPEUTICS INC New — 4,000 +4,000 $ 422.44K
ALUMIS INC New — 18,800 +18,800 $ 410.028K
PRAXIS PRECISION MEDICINES INC. New — 1,000 +1,000 $ 350.3K
VEEVA SYS INC Sold 4,188 3,000 −1,188 $ -339.4K
ALIGN TECHNOLOGY INC Closed 1,863 — −1,863 $ -325.932K
BRUKER CORP New — 5,400 +5,400 $ 313.254K
REPLIGEN CORP Bought 2,485 4,200 +1,715 $ 310.381K
XENON PHARMACEUTICALS INC Sold 14,366 9,266 −5,100 $ -307.122K
CARIS LIFE SCIENCES INC Sold 41,991 30,000 −11,991 $ -305.651K
ALNYLAM PHARMACEUTICALS INC Bought 3,791 5,000 +1,209 $ 290.994K
DANAHER CORP Bought 7,675 9,000 +1,325 $ 282.967K
BRAVEHEART BIO INC New — 10,000 +10,000 $ 255K
PHARVARIS BV
New — 7,100 +7,100 $ 245.731K
ARGENX SE Bought 1,365 1,600 +235 $ 242.44K
DEXCOM INC Sold 6,533 4,000 −2,533 $ -230.655K
CG ONCOLOGY INC New — 2,800 +2,800 $ 210.448K
SPYRE THERAPEUTICS INC Bought 300 2,600 +2,300 $ 205.459K
RELAY THERAPEUTICS INC Bought 12,996 24,000 +11,004 $ 202.254K
CLIMB BIO INC New — 14,400 +14,400 $ 197.712K
DEFINIUM THERAPEUTICS INC New — 4,800 +4,800 $ 190.656K
KYMERA THERAPEUTICS INC Sold 10,000 8,500 −1,500 $ -178.215K
PROCEPT BIOROBOTICS CORP Closed 6,656 — −6,656 $ -175.252K
ROIVANT SCIENCES LTD Bought 11,250 16,250 +5,000 $ 173.2K
JADE BIOSCIENCES INC New — 7,426 +7,426 $ 158.619K
BRIGHTSPRING HEALTH SERVICES INC Bought 10,187 12,800 +2,613 $ 152.599K
ALIGNMENT HEALTHCARE INC Sold 33,378 22,200 −11,178 $ -149.785K
10X GENOMICS INC Sold 45,000 42,800 −2,200 $ -137.39K
UNITEDHEALTH GROUP INC Sold 2,424 2,100 −324 $ -126.169K
ANNEXON INC New — 24,000 +24,000 $ 118.56K
MBX BIOSCIENCES INC Bought 5,128 7,000 +1,872 $ 115.315K
INSMED INC Bought 6,875 7,775 +900 $ 109.638K
NEWAMSTERDAM PHARMA COMPANY NV
Bought 11,122 15,000 +3,878 $ 98.269K
GUARDANT HEALTH INC Bought 4,375 4,975 +600 $ 95.412K
KESTRA MEDICAL TECHNOLOGIES INC Bought 18,400 22,000 +3,600 $ 92.7K
VAXCYTE INC Bought 14,071 15,571 +1,500 $ 91.11K
HEARTFLOW INC Bought 24,994 26,500 +1,506 $ 75.887K
ENLIVEN THERAPEUTICS INC Bought 10,703 12,000 +1,297 $ 75.083K
VERACYTE INC Sold 13,621 12,021 −1,600 $ -69.104K
WAYSTAR HOLDING CORP Sold 20,187 18,000 −2,187 $ -57.256K
OLEMA PHARMACEUTICALS INC Bought 11,250 14,950 +3,700 $ 38.591K
LEGEND BIOTECH CORP Bought 34,614 36,000 +1,386 $ 28.801K
COGENT BIOSCIENCES INC Bought 33,428 34,000 +572 $ 20.02K
INTUITIVE SURGICAL INC Sold 2,816 2,800 −16 $ -6,029.76

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up